

ISOMORPHIC LABS ANNOUNCES NOVARTIS COLLABORATION EXPANSION

Deeper collaboration established between the parties, expanding the scope of the original collaboration to add up to three additional research programs

LONDON, February 18, 2025 - Isomorphic Labs (IsoLabs), an AI-first drug design company, today announced that it has entered into an agreement to expand its strategic research collaboration with Novartis. This follows the [announcement of IsoLabs' research collaboration](#) with Novartis on 7 January, 2024.

Under the terms of the agreement, IsoLabs and Novartis will expand the scope of the initial collaboration, adding up to three additional research programs on the same financial terms as the original agreement. This expansion is testament to the great collaboration and progress of research programs made in one year, amplifying the synergy between the parties and further unlocking the potential of combined expertise, data, and technological capabilities to accelerate shared goals.

“I’ve long believed that there is no more important application for AI than helping improve human health,” said Demis Hassabis, Isomorphic Labs’ CEO. “We are delighted to expand and strengthen our deep collaboration with Novartis, and it serves as further evidence of the enormous potential impact AI will have on accelerating drug discovery”.

Fiona Marshall, President of Biomedical Research at Novartis said, “We are thrilled to expand our relationship with Isomorphic Labs. We selected particularly challenging targets for our initial programs with Isomorphic because we appreciate the remarkable potential of their AI-driven capabilities in drug discovery and design. Over the past year we have witnessed the exploration of new chemical spaces that would be unavailable to probe through traditional methods, and I look forward to continuing our work together on additional difficult targets with the potential to address significant unmet patient needs.”

ABOUT ISOMORPHIC LABS

Isomorphic Labs was founded in 2021, building on the success of AlphaFold 2, and with a distinct focus on the application of AI to drug discovery to advance a new era of medical breakthroughs. Isomorphic Labs was founded and is led by AI pioneer Sir Demis Hassabis and is backed by Alphabet, Google’s parent company.

For more information, go to www.isomorphiclabs.com or follow us on [LinkedIn](#) and [X](#).

For Media Inquiries

press@isomorphiclabs.com